Boston Scientific (NYSE:BSX) Updates FY 2025 Earnings Guidance

Boston Scientific (NYSE:BSX - Get Free Report) updated its FY 2025 earnings guidance on Wednesday. The company provided earnings per share guidance of 2.870-2.940 for the period, compared to the consensus earnings per share estimate of 2.860. The company issued revenue guidance of $19.3 billion-$19.6 billion, compared to the consensus revenue estimate of $19.1 billion. Boston Scientific also updated its Q2 2025 guidance to 0.710-0.730 EPS.

Analysts Set New Price Targets

Several research firms recently issued reports on BSX. Stifel Nicolaus upped their price target on Boston Scientific from $100.00 to $115.00 and gave the company a "buy" rating in a research report on Thursday, February 6th. Truist Financial increased their target price on shares of Boston Scientific from $113.00 to $117.00 and gave the stock a "buy" rating in a report on Thursday. Royal Bank of Canada raised their price target on shares of Boston Scientific from $116.00 to $120.00 and gave the stock an "outperform" rating in a research report on Thursday. Barclays boosted their price objective on shares of Boston Scientific from $118.00 to $125.00 and gave the company an "overweight" rating in a research report on Friday. Finally, Morgan Stanley raised their target price on shares of Boston Scientific from $100.00 to $120.00 and gave the stock an "overweight" rating in a report on Thursday, February 6th. One investment analyst has rated the stock with a hold rating, twenty-two have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus target price of $114.52.

Boston Scientific Price Performance

NYSE BSX traded down $0.24 on Monday, reaching $101.66. 3,304,541 shares of the stock traded hands, compared to its average volume of 6,345,407. The company has a quick ratio of 1.02, a current ratio of 1.08 and a debt-to-equity ratio of 0.41. The company has a market cap of $150.37 billion, a price-to-earnings ratio of 81.32, a P/E/G ratio of 2.79 and a beta of 0.73. The firm's fifty day simple moving average is $98.68 and its 200 day simple moving average is $94.92. Boston Scientific has a 12 month low of $70.97 and a 12 month high of $107.17.

Boston Scientific (NYSE:BSX - Get Free Report) last released its earnings results on Wednesday, April 23rd. The medical equipment provider reported $0.75 EPS for the quarter, topping analysts' consensus estimates of $0.67 by $0.08. The business had revenue of $4.66 billion for the quarter, compared to the consensus estimate of $4.57 billion. Boston Scientific had a net margin of 11.07% and a return on equity of 17.80%. The business's revenue for the quarter was up 20.9% on a year-over-year basis. During the same period in the previous year, the firm earned $0.56 EPS. As a group, research analysts predict that Boston Scientific will post 2.85 EPS for the current fiscal year.

Insider Activity

In other news, EVP Arthur C. Butcher sold 17,313 shares of the firm's stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $101.80, for a total transaction of $1,762,463.40. Following the completion of the sale, the executive vice president now directly owns 5,502 shares of the company's stock, valued at $560,103.60. This trade represents a 75.88 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Daniel J. Brennan sold 67,333 shares of the firm's stock in a transaction that occurred on Wednesday, February 19th. The shares were sold at an average price of $105.24, for a total transaction of $7,086,124.92. Following the transaction, the chief financial officer now directly owns 225,808 shares in the company, valued at approximately $23,764,033.92. The trade was a 22.97 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 138,009 shares of company stock worth $14,407,381. 0.50% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Boston Scientific stock. Brighton Jones LLC increased its position in shares of Boston Scientific Co. (NYSE:BSX - Free Report) by 0.8% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 27,376 shares of the medical equipment provider's stock after buying an additional 226 shares during the period. Brighton Jones LLC's holdings in Boston Scientific were worth $2,445,000 at the end of the most recent reporting period. 89.07% of the stock is currently owned by institutional investors.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.